Nabriva Therapeutics plc financial data

Industry
Pharmaceutical Preparations
Location
25 28 North Wall Quay, Dublin, Ireland
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Nabriva Therapeutics AG (to 7/10/2017)
Latest financial report
10-Q - Q2 2023 - Oct 19, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 109 % -70.7%
Quick Ratio 53.4 % -25.8%
Debt-to-equity 1.3K % +2575%
Return On Equity -2.67K % -2708%
Return On Assets -192 % -199%
Operating Margin -183 % -41.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.23M shares +5.45%
Common Stock, Shares, Outstanding 3.23M shares -95%
Entity Public Float 11.6M USD -82.8%
Common Stock, Value, Issued 32K USD -95%
Weighted Average Number of Shares Outstanding, Basic 3.23M shares +27.7%
Weighted Average Number of Shares Outstanding, Diluted 3.23M shares +27.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 29.6M USD -16.4%
Cost of Revenue 34.3M USD +98.4%
Research and Development Expense 10.4M USD -21.5%
Costs and Expenses 83.6M USD +3.21%
Operating Income (Loss) -54M USD -18.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -54.2M USD -17.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -55.1M USD -18.1%
Earnings Per Share, Basic -18.4 USD/shares +50.5%
Earnings Per Share, Diluted -18.4 USD/shares +50.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.18M USD -89.1%
Cash, Cash Equivalents, and Short-term Investments 34M USD -38.2%
Accounts Receivable, after Allowance for Credit Loss, Current 3.21M USD -63.5%
Inventory, Net 9.03M USD -42.3%
Assets, Current 9.95M USD -81.7%
Property, Plant and Equipment, Net 246K USD +19.4%
Intangible Assets, Net (Excluding Goodwill) 1K USD -92.3%
Other Assets, Noncurrent 379K USD +0.27%
Assets 10.6M USD -80.7%
Accounts Payable, Current 14M USD +1207%
Employee-related Liabilities, Current 3.04M USD -9.06%
Accrued Liabilities, Current 12M USD +2.97%
Liabilities, Current 26.2M USD +35.5%
Other Liabilities, Noncurrent 352K USD -20.7%
Liabilities 26.9M USD +32.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 27K USD 0%
Retained Earnings (Accumulated Deficit) -674M USD -8.9%
Stockholders' Equity Attributable to Parent -16.3M USD -147%
Liabilities and Equity 10.6M USD -80.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.62M USD +64.6%
Net Cash Provided by (Used in) Financing Activities -4.85M USD -321%
Net Cash Provided by (Used in) Investing Activities -3K USD +91.7%
Common Stock, Shares Authorized 12M shares -96%
Common Stock, Shares, Issued 3.23M shares -95%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.6M USD +23.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.26M USD -88.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 162K USD +31.7%
Deferred Tax Assets, Valuation Allowance 123M USD +3.96%
Deferred Tax Assets, Gross 124M USD +4.17%
Lessee, Operating Lease, Liability, to be Paid 498K USD
Property, Plant and Equipment, Gross 4.8M USD +4.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 892K USD +27.1%
Deferred Tax Assets, Operating Loss Carryforwards 116M USD +4.37%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 21K USD -73.1%
Deferred Tax Assets, Net of Valuation Allowance 363K USD +230%
Share-based Payment Arrangement, Expense 1.73M USD -70.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%